Clinical trials: Allergy; Dermatitis
Healthy, Atopic Dermatitis
A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis
The main purpose of this study is to evaluate the safety and tolerability of LY3872386 in healthy participants and participants with atopic dermatitis. The safety of prednisone is also evaluated in healthy participants.
- Trial name
- NCT06119529
- Testing
- LY3872386, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis
The purpose of this study is to evaluate the potential improvement in atopic dermatitis signs and symptoms following the application of FB-401 in patients 2 years or older with mild to moderate atopic dermatitis.
- Trial name
- NCT04504279
- Testing
- FB-401
- Where
- 15 sites in United States
- Volunteers
- 154 people
- Sponsor
- Forte Biosciences, Inc.
Skin Diseases
A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric Subjects With Stabilized Atopic Dermatitis
This is an open-label, randomized, comparative study, including 4 phases: SCREENING, ACUTE, MAINTENANCE and FOLLOW-UP. Subjects will complete the SCREENING phase to check the eligibility within 7 days after they sign the written…
- Trial name
- NCT01915914
- Testing
- Fluticasone propionate
- Where
- 4 sites in China
- Volunteers
- 107 people
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis
A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to evaluate the safety and efficacy of lebrikizumab compared with placebo in participants with moderate-to-severe atopic dermatitis.
- Trial name
- NCT03443024
- Testing
- Lebrikizumab
- Where
- 58 sites in United States
- Volunteers
- 280 people
- Sponsor
- Eli Lilly and Company
Dermatitis, Contact
A Study To Assess Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Patients
This study will be a prospective, non-interventional, single arm and open label study, in patients with contact dermatitis requiring systemic steroid therapy with a purpose to obtain the real life effectiveness and tolerability…
- Trial name
- NCT00929981
- Testing
- Tablet Methylprednisolone (4 or 16 mg)
- Where
- 4 sites in India
- Volunteers
- 80 people
- Sponsor
- Pfizer
Atopic Dermatitis (AD), Eczema
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
This is a first-in-human, Phase 1, double-blind, randomized, placebo-controlled, dose-escalation study evaluating ARQ-234. The study is designed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD)…
- Trial name
- NCT07453602
- Testing
- ARQ-234
- Where
- 7 sites in United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Arcutis Biotherapeutics, Inc.
Atopic Dermatitis
Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis
This is the first time PF-07242813 will be given to humans. The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07242813 in healthy participants and…
- Trial name
- NCT04668066
- Testing
- PF-07242813
- Where
- 7 sites in United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Pfizer
Dermatitis, Atopic
Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis
The primary objective of the study was to evaluate the safety and pharmacokinetic of 611 in Chinese children and adolescents with moderate to severe atopic dermatitis.
- Trial name
- NCT06324812
- Testing
- Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611)
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Dermatitis, Atopic
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to severe atopic dermatitis and have completed a qualifying parent study.
- Trial name
- JADE EXTEND (NCT03422822)
- Testing
- Abrocitinib 100 mg, Abrocitinib 200 mg
- Where
- 539 sites in United States, Argentina and 26 more
- Volunteers
- 3,166 people
- Sponsor
- Pfizer
Atopic Dermatitis
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with atopic dermatitis.
- Trial name
- NCT03568331
- Testing
- Tradipitant
- Where
- 70 sites in United States
- Volunteers
- 375 people
- Sponsor
- Vanda Pharmaceuticals
Atopic Dermatitis, Atopic
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.
- Conditions
- Atopic Dermatitis, Atopic, Dermatitis, AD
- Trial name
- NCT07011706
- Testing
- ATI-045
- Where
- 60 sites in United States, Canada
- Volunteers
- 110 people
- Sponsor
- Aclaris Therapeutics, Inc.
Dermatitis, Atopic, Eczema
Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis
This is a 13 week randomized, double blind, parallel group, in home use study among approximately 60 male and female subjects, ages 12 to 65 years old inclusive, with atopic dermatitis (AD) SCORAD >16.
- Trial name
- NCT02732314
- Testing
- Investigational OTC Cream, Cosmetic Eczema Cream, 0.05% Desonide Cream
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Procter & Gamble Beauty
Atopic Dermatitis
A Phase 1 Trial of OPA-15406 Ointment in Healthy Adult Male Subjects
To assess the safety (especially skin findings) and pharmacokinetics by applying 0.3%, 1%, or 3% formulation of 5g OPA-15406 ointment to a 1000 cm2 area as a single-dose and as a multiple-dose twice daily for 2 weeks in Japanese…
- Trial name
- NCT02334787
- Testing
- 0.3% OPA-15406 Ointment, 1% OPA-15406 Ointment, 3% OPA-15406 Ointment
- Where
- Japan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Pruritus, Atopic Dermatitis
A Study of the Efficacy and Safety of Orvepitant in Subjects With Pruritus Associated With Atopic Dermatitis
The purpose of this study is to determine the effectiveness of three doses of orvepitant, taken once a day, in the treatment of pruritus associated with atopic dermatitis.
- Trial name
- SOOTHE (NCT03464526)
- Testing
- Orvepitant
- Sponsor
- Nerre Therapeutics Ltd.
Atopic Dermatitis
Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic Dermatitis
The purpose of this study is to evaluate the efficacy and safety of Jaktinib in participants with moderate to severe atopic dermatitis.
- Trial name
- AD (NCT04539639)
- Testing
- Jaktinib
- Where
- China
- Volunteers
- 166 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Atopic Dermatitis
A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis
This is an observational study to assess the long-term safety of Protopic® Ointment for the treatment of atopic dermatitis. Patients whose ages are/were < 16 years at the time of first tacrolimus ointment exposure are eligible to…
- Trial name
- APPLES (NCT00475605)
- Where
- 313 sites in United States, Austria and 7 more
- Volunteers
- 8,071 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Atopic Dermatitis
This was a randomized, double blind, placebo controlled, parallel group study in approximately 90 subjects with moderate-severe AD Eczema Area and Severity Index (EASI) ≥12 and ≤ 48 (0-72 scale).
- Trial name
- NCT02424253
- Testing
- ZPL-3893787
- Where
- 17 sites in Belgium, Germany and 2 more
- Volunteers
- 98 people
- Sponsor
- Ziarco Pharma Ltd
Atopic Dermatitis (AD)
A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis
To investigate the efficacy of 0.3% OPA-15406 ointment when administered twice daily for 4 weeks in infants younger than 2 years of age with Atopic Dermatitis
- Trial name
- NCT05372653
- Testing
- OPA-15406
- Where
- Japan
- Volunteers
- 41 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Atopic Dermatitis
Phase 2b Study of EVO756 in Adults With Atopic Dermatitis
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.
- Trial name
- NCT07150845
- Testing
- EVO756
- Where
- 29 sites in United States, New Zealand
- Volunteers
- 121 people
- Sponsor
- Evommune, Inc.
Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis
Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.
Patients diagnosed with Stevens-Johnson syndrome and Toxic Epidermal Necrolysis were confirmed based on the investigators national diagnostic criteria.
- Trial name
- NCT01696500
- Testing
- Intravenous immunoglobulin
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Nihon Pharmaceutical Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.